EICHOR
● Recruiting
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
Condition: SCLC, Extensive Stage · Advanced Solid Tumors · Sponsor: Shanghai AB PharmaTech Ltd.
About this study
This study is a multicenter, open-label, multi-cohort investigation exploring the efficacy and safety of ABP1011T tablets in participants with specific target solid tumors, providing a foundation for subsequent clinical research. Based on safety and efficacy data from the prior Phase I/IIa clinical trial (Protocol Number: ABP1011T-I/II-01), priority enrollment is given to participants with advanced solid tumors including small cell lung cancer, esophageal cancer, cervical cancer, bladder cancer, and renal cell carcinoma (excluding osteosarcoma). Cohort A (Cohort A1, Cohort A2, Cohort A3) comprises the small cell lung cancer cohort: Participants must have failed at least two prior systemic therapies. Cohort B enrolls participants with other advanced solid tumors (excluding osteosarcoma). ABP1011T tablets are administered as continuous therapy in clinical studies, with a 21-day treatment cycle. Participants take one tablet orally once daily on an empty stomach (with water, avoiding food for at least 1 hour before and after each dose).
This description comes directly from the study's public registry record.
Talk to the study team
Haiping WANG, PhD · +86 21 5442 6122 · hpwang@abpharma.com
Always discuss trial participation with your own doctor first.
Locations (8)
| The First Affiliated Hospital of Henan University of Science and Technology | Luoyang, Henan, China | Not Yet Recruiting |
| The First Affiliated Hospital of Nanyang Medical College | Nanyang, Henan, China | Not Yet Recruiting |
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Not Yet Recruiting |
| Liaocheng Second People's Hospital | Liaocheng, Shandong, China | Recruiting |
| Shanghai Pulmonary Hospital | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| Shanxi Bethune Hospital | Taiyuan, Shanxi, China | Not Yet Recruiting |
| Neijiang First People's Hospital | Neijiang, Sichuan, China | Recruiting |
| Shanghai East Hospital | Shanghai, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07321574